Nuvectis Pharma, Inc.
NVCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875558
No open-market purchases or sales by Nuvectis Pharma, Inc. insiders were filed in the last 90 days; 82 institutions reported holding it in 13F filings for Q2 2026, worth $189.0M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Nuvectis Pharma, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 41 | 1 | 31 | −9 |
| Shares | 1.21M | 83.4K | 1.05M | −72.3K (−6.4%) |
| Value | $7.63M | $528.0K | $6.60M | −$499.5K (−7.0%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (4)
Institutions that held Nuvectis Pharma, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Iridian Asset Management LLC | 55,380 | $348.3K | 0.07% |
| BlackRock, Inc. | 49,554 | $311.7K | 0.00% |
| Susquehanna International Group, LLP | 26,463 | $166.5K | 0.00% |
| Nations Financial Group Inc, | 10,000 | $62.9K | 0.00% |
Sold out (13)
Institutions that held Nuvectis Pharma, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Goldman Sachs Group Inc | 61,570 | $389.7K |
| Y-Intercept (Hong Kong) Ltd | 23,173 | $146.7K |
| Jane Street Group, LLC | 17,021 | $107.7K |
| Citadel Advisors LLC | 14,937 | $94.6K |
| HRT Financial LP | 13,627 | $86.0K |
| Centiva Capital, LP | 13,300 | $84.2K |
| Point72 Asia (Singapore) Pte. Ltd. | 9,203 | $58.3K |
| Mirae Asset Global ETFs Holdings Ltd. | 3,254 | $20.6K |
| Rhumbline Advisers | 1,871 | $11.8K |
| Point72 (DIFC) Ltd | 1,249 | $7.91K |
| Macquarie Group Ltd | 355 | $2.25K |
| New York State Common Retirement Fund | 64 | $405 |
| CWM, LLC | 16 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held Nuvectis Pharma, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 83,412 | $528.0K |